Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a potent and selective inhibitor of big MAP kinase 1

ACS Medicinal Chemistry Letters

Volumn 2, Issue 3, 2011, Pages 195-200

  Deng, Xianming ^a   Yang, Qingkai ^b   Kwiatkowski, Nicholas ^a   Sim, Taebo ^a   McDermott, Ultan ^a   Settleman, Jeffrey E ^a   Lee, Jiing Dwan ^b   Gray, Nathanael S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

BMK1; ERK5; MAPK

Indexed keywords

2 AMINO 5,11 DIMETHYL 5H BENZO[E]PYRIMIDO[5,4 B][1,4]DIAZEPIN 6 (11H) ONE; 3 ((( 3 ((DIMETHYLAMINO)METHYL)PHENYL)AMINO)(PHENYL)METHYLENE)2 OXOINDOLINE 6 CARBOXAMIDE; 4 ((( 3 (DIMETHYLAMINO)METHYL)PHENYL)AMINO)(PHENYL)METHYLENE) N,N DIMETHYL 2 OXOINDOLINE 6 CARBOXAMIDE; BENZO[E]PYRIMIDO[5,4 B][1,4]DIAZEPIN 6 (11H) ONE; BIX 02188; BIX 02189; DIAZEPINE DERIVATIVE; EPIDERMAL GROWTH FACTOR; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE 7 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; AUTOPHOSPHORYLATION; CELL PROLIFERATION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IC 50; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 79952661147     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml100304b     Document Type: Article

References (21)

1. Widmann, C.; Gibson, S.; Jarpe, M. B.; Johnson, G. L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human Physiol. Rev. 1999, 79, 143-80 (Pubitemid 29056951)
2. Chang, L.; Karin, M. Mammalian MAP kinase signalling cascades Nature 2001, 410, 37-40 (Pubitemid 32225829)
3. Lee, J. D.; Ulevitch, R. J.; Han, J. Primary structure of BMK1: a new mammalian map kinase Biochem. Biophys. Res. Commun. 1995, 213, 715-724
4. Zhou, G.; Bao, Z. Q.; Dixon, J. E. Components of a new human protein kinase signal transduction pathway J. Biol. Chem. 1995, 270, 12665-12669
5. English, J. M.; Vanderbilt, C. A.; Xu, S.; Marcus, S.; Cobb, M. H. Isolation of MEK5 and differential expression of alternatively spliced forms J. Biol. Chem. 1995, 270, 28897-28902
6. Hayashi, M.; Lee, J. D. Role of the BMK1/ERK5 signaling pathway: lessons from knockout mice J. Mol. Med. 2004, 82, 800-808
7. Wang, X.; Tournier, C. Regulation of cellular functions by the ERK5 signalling pathway Cell. Signalling 2006, 18, 753-60 (Pubitemid 43208930)
8. Mehta, P. B.; Jenkins, B. L.; McCarthy, L.; Thilak, L.; Robson, C. N.; Neal, D. E.; Leung, H. Y. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion Oncogene 2003, 22, 1381-9 (Pubitemid 36384600)
9. Esparis-Ogando, A.; Diaz-Rodriguez, E.; Montero, J. C.; Yuste, L.; Crespo, P.; Pandiella, A. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2 Mol. Cell. Biol. 2002, 22, 270-85 (Pubitemid 33144274)
10. Weldon, C. B.; Scandurro, A. B.; Rolfe, K. W.; Clayton, J. L.; Elliott, S.; Butler, N. N.; Melnik, L. I.; Alam, J.; McLachlan, J. A.; Jaffe, B. M.; Beckman, B. S.; Burow, M. E. Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray Surgery 2002, 132, 293-301 (Pubitemid 35024776)
11. Tatake, R. J.; O'Neill, M. M.; Kennedy, C. A.; Wayne, A. L.; Jakes, S.; Wu, D.; Kugler, S. Z., Jr.; Kashem, M. A.; Kaplita, P.; Snow, R. J. Identification of pharmacological inhibitors of the MEK5/ERK5 pathway Biochem. Biophys. Res. Commun. 2008, 377, 120-125
12. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 2009, 9, 28-39
13. Lenart, P.; Petronczki, M.; Steegmaier, M.; Di Fiore, B.; Lipp, J. J.; Hoffmann, M.; Rettig, W. J.; Kraut, N.; Peters, J. M. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1 Curr. Biol. 2007, 17, 304-315
14. Steegmaier, M.; Hoffmann, M.; Baum, A.; Lenart, P.; Petronczki, M.; Krssak, M.; Gurtler, U.; Garin-Chesa, P.; Lieb, S.; Quant, J.; Grauert, M.; Adolf, G. R.; Kraut, N.; Peters, J. M.; Rettig, W. J. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo Curr. Biol. 2007, 17, 316-322 (Pubitemid 46241881)
15. Sapkota, G. P.; Cummings, L.; Newell, F. S.; Armstrong, C.; Bain, J.; Frodin, M.; Grauert, M.; Hoffmann, M.; Schnapp, G.; Steegmaier, M.; Cohen, P.; Alessi, D. R. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo Biochem. J. 2007, 401, 29-38 (Pubitemid 46114597)
16. Fabian, M. A.; Biggs, W. H., 3rd; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J. M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 2005, 23, 329-336 (Pubitemid 41094421)
17. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26, 127-132
18. Abe, J.; Kusuhara, M.; Ulevitch, R. J.; Berk, B. C.; Lee, J. D. Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase J. Biol. Chem. 1996, 271, 16586-16590 (Pubitemid 26239014)
19. Okram, B.; Nagle, A.; Adrian, F. J.; Lee, C.; Ren, P.; Wang, X.; Sim, T.; Xie, Y.; Wang, X.; Xia, G.; Spraggon, G.; Warmuth, M.; Liu, Y.; Gray, N. S. A general strategy for creating "inactive-conformation" abl inhibitors Chem. Biol. 2006, 13, 779-786 (Pubitemid 44109805)
20. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2006, 2, 358-364 (Pubitemid 43936934)
21. Yang, Q.; Deng, X.; Lu, B.; Cameron, M.; Fearns, C.; Patricelli, M. P.; Yates, J. R., III; Gray, N. S.; Lee, J.-D. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein Cancer Cell 2010, 18, 258-267